<DOC>
	<DOCNO>NCT02258009</DOCNO>
	<brief_summary>The purpose study compare effect intravitreal injection ranibizumab aflibercept systemic VEGF protein level DME patient detailed time course .</brief_summary>
	<brief_title>Systemic VEGF Protein Dynamics Following Intravitreal Injections Ranibizumab Versus Aflibercept Patients With Visual Impairment Due Diabetic Macular Edema</brief_title>
	<detailed_description />
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Vision Disorders</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Type 1 Type 2 diabetes mellitus Visual impairment predominantly due DME . Stroke myocardial infarction le 3 month prior screen . Presence uncontrolled systolic blood pressure diastolic blood pressure Renal failure require dialysis renal transplant renal insufficiency Untreated diabetes mellitus Use systemic antiVEGF drug Use systemic inhale corticosteroid least 30 consecutive day within 3 month prior screen . Women pregnant breast feed menstruate capable become pregnant* practice medically approve method contraception For either eye : Any active periocular ocular infection inflammation Uncontrolled glaucoma Neovascularization iris neovascular glaucoma History treatment antiangiogenic drug For study eye : Atrophy fibrosis involve center fovea time screen baseline . Cataract ( cause significant visual impairment ) , plan cataract surgery study period , vitrectomy , aphakia , glaucoma surgery , severe vitreous hemorrhage , rhegmatogenous retinal detachment , proliferative retinopathy choroidal neovascularization macular edema cause DME Irreversible structural damage within 0.5 disc diameter center macula Panretinal laser photocoagulation within 6 month prior randomization . Focal/grid laser photocoagulation within 3 month prior randomization . Any intraocular procedure ( include cataract surgery , YttriumAluminumGarnet capsulotomy ) within 3 month prior baseline anticipate within next 6 month follow Topical ocular corticosteroid administer least 30 consecutive day within 3 month prior screen . Application intravitreal corticosteroid vitreous within 6 month prior screen . Prior application fluocinolonacetonid release implant vitreous within 36 month prior screen . For fellow eye Retinal choroidal neovascularization macula edema cause Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2016</verification_date>
</DOC>